374
U N I T 4
Infection and Immunity
51. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and
HCV infections among antibody-negative blood donors by nucleic
acid-amplification testing.
N Engl J Med.
2004;351:760–768.
52. Centers for Disease Control and Prevention.
Occupational
HIV transmission among healthcare workers
. 2011. Available
at:
/ hcwprev.htm.
Accessed August 26, 2013.
53. Kuhar DT, Henderson DK, Struble KA, et al.; for the USPHS
Writing Group. Updated U.S. Public Health Service guidelines
for the management of occupational exposures to human
immunodeficiency virus and recommendations for postexposure
prophylaxis.
Infect Control Hosp Epidemiol.
2013;34(9):875–892.
54. Brenner BG, Roger M, Routy JP, et al. Amplified transmission in
early HIV infection.
J Infect Dis.
2007;195:951–959.
55. Trecarichi EM, Tumbarello M, de Gaetano Donati K, et al.
Partial protective effect of CCR5-delta 32 heterozygosity in
a cohort of heterosexual Italian HIV-1 exposed uninfected
individuals.
AIDS Res Ther.
2006;3:22.
56. Centers for Disease Control and Prevention. 1993 Revised
classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults.
Morb
Mortal Wkly Rep.
1992;41(RR-17):1–23.
57. Schneider E, Whitmore S, Glynn MK, et al. Revised surveillance
case definitions for HIV infections among adults, adolescents,
and children aged <18 months and for children aged 18 months
to <13 years–United States, 2008.
MMWR Recomm Rep.
2008;57(RR-10),1–8.
58. Hecht FM, Wang L, Collier A. A multicenter observational study
of potential benefits of initiating combination antiretroviral
therapy during acute infection.
J Infect Dis.
2006;194:725–733.
59. Rodriguez B, Sethi AK, Cheruvu VK. Predictive value of plasma
HIV RNA level on rate of CD4 T-cell decline in untreated HIV
infection.
JAMA.
2006;296:1498–1506.
60. Casaa C, Solomba S, Rauch A, et al. Host and viral genetic
correlates of clinical definitions of HIV-1 progression.
PLoS One.
2010;5(6):e11079.
61. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of
HIV associated opportunistic infections in the United States in
the era of highly active antiretroviral therapy.
Clin Infect Dis.
2000;30(suppl 1):S5–S14.
62. UNAIDS.
Frequently asked questions about tuberculosis
. 2006.
Available at:
hiv_
qa.pdf. Accessed August 26, 2013.
63. Wilcox CM. Gastrointestinal manifestations of AIDS.
Nutr Clin
Pract.
2004;19:356–364.
64. Antinori A, Arendt G, Becker JT. Updated research nosology
for HIV-associated neurocognitive disorders.
Neurology.
2007;69:1789–1799.
65. Dedicoat M, Livesley N. Management of toxoplasmic encephalitis
in HIV-infected adults (with an emphasis on resource-poor
settings).
Cochrane Database Syst Rev.
2006;19(3):CD005420.
66. Berger JR, Houff S. Progressive multifocal leukoencephalopathy:
lessons from AIDS and natalizumab.
Neurol Res.
2006;28:299–305.
67. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining
malignancies: cancer occurrence in the antiretroviral therapy era.
Curr Opin Oncol.
2007;19:446–451.
68. Antman K, Chang Y. Kaposi’s sarcoma.
N Engl J Med.
2000;342:1027–1038.
69. De Vuyst H, Franceschi S. Human papillomavirus vaccines in HIV-
positive men and women.
Curr Opin Oncol.
2007;19:470–475.
70. Polsky B, Kotler D, Steinhart C. Treatment guidelines for HIV-
associated wasting.
HIV Clin Trials.
2004;5:50–61.
71. Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk
factors for future cardiovascular disease among HIV-infected
patients.
Curr HIV/AIDS Rep.
2005;2:132–139.
72. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the
prevalence and incidence of diabetes mellitus in the multicenter
AIDS cohort study.
Arch Intern Med.
2005;165:1179–1184.
73. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy
and related factors.
Atherosclerosis.
2004;174:1–10.
74. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of
changes in central and peripheral fat following initiation of
antiretroviral therapy in a randomized trial.
J Acquir Immune
Defic Syndr.
2006;41:590–597.
75. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities
in HIV-infected adults.
N Engl J Med.
2005;352:48–62.
76. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient
monitoring and toxicity management.
J Acquir Immune Defic
Syndr.
2004;37(suppl 1):S30–S35.
77. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines
for the management of persons infected with human
immunodeficiency virus: 2009 update by the HIV Medicine
Association of the Infectious Diseases Society of America.
Clin
Infect Dis.
2009;49(5):651–681.
78. Delaney KP, Branson BM, Uniyal A, et al. Performance of an
oral rapid HIV-1/2 test experience with four CDC studies.
AIDS.
2006;20:1655–1660.
79. Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents.
Department of Health and Human
Services.
Updated February 12, 2013; 1–161. Available at: http://
AdolescentGL.pdf.
Accessed August 26, 2013.
80. Maplanka C. AIDS: is there an answer to the global pandemic?
The immune system in HIV infection and control.
Viral
Immunol.
2007;20:331–342.
81. McIntyre J. Managing pregnant patients. In: Dolin R, Masur
H, Saag M, eds.
AIDS Therapy
. 3rd ed. London, UK: Churchill
Livingston; 2008:595–597.
82. Yogev R, Chadwick EG. Acquired immunodeficiency syndrome
(human immunodeficiency virus). In: Behrman RE, Kliegman
RM, Jenson HB, et al., eds.
Nelson Textbook of Pediatrics
. 18th
ed. Philadelphia, PA: Saunders Elsevier; 2007:1427–1443.
83. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-
infant transmission of human immunodeficiency virus type 1
with zidovudine treatment.
N Engl J Med.
1994;33:1173–1180.
84. Panel on Treatment of HIV-Infected Pregnant Women and
Prevention of Perinatal Transmission.
Recommendations for
use of antiretroviral drugs in pregnant HIV-1-infected women
for maternal health and interventions to reduce perinatal HIV
transmission in the United States
. 2012. Available at: http://
AIDSinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf.
Accessed August 26, 2013.
85. Centers for Disease Control and Prevention, the National
Institutes of Health, the HIV Medicine Association of Infectious
Diseases Society of America, the Pediatric Infectious Disease
Society, and the American Academy of Pediatrics.
Guidelines for
Prevention and Treatment of Opportunistic Infections Among
HIV-Exposed and HIV-Infected Children
. 2009. Available at:
pediatrics.pdf. Accessed August 26, 2013.
Porth Essentials Resources
Explore these additional resources to enhance learning
for this chapter:
•
NCLEX-Style Questions and Other Resources
on
,
•
Study Guide for Essentials of Pathophysiology
•
Concepts in Action Animations
•
Adaptive Learning | Powered by PrepU,
prepu
